Kadimastem on Tel-Aviv Stock Exchange

For More Investors Info.
Kadimastem Announces Executive Management Changes

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

Kadimastem Appoints Ruth Alon as Chairperson of the Company's Board of Directors

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

Kadimastem Announces the Completion of Treatment for Cohort B

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

Kadimastem Announces Leadership Changes

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

Appointment of a new CFO for Kadimastem

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

Kadimastem to be included in the TASE Indices

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

Kadimastem and The AFDR Selected to Receive a bi-National Grant

Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial

Kadimastem was honored with a prize for excellence for the presentation of the company's technology

Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:

Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published

Successful Public Offering for Kadimastem

Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients

Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes

Successful Rights Offering for Kadimastem; Raised NIS 5.1M

Kadimastem to Raise up to NIS 10M in Rights Offering

Kadimastem Received Response from FDA:

Kadimastem Approached the FDA Regarding Its ALS Treatment

Kadimastem to collaborate with Merck Serono to advance efforts in neurodegenerative diseases

Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS

Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS

Kadimastem Receives Approval for U.S. Patent

Leading pharma entrepreneur Avi Meizler believes in Kadimastem!

Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)

Kadimastem Augments the Company's ALS Activities

Kadimastem has received approval from the OCS to promote cell therapy

Merck Serono and Kadimastem MOU on Drug Screening and Discovery for Neurodegenerative Diseases

Kadimastem successfully completes an IPO and raised $5.5 Million USD

Pharmaceutical Company Merck Serono signs an agreement: Use Kadimastem's platform for drug screening

Dr. Eli Opper, joined Kadimastem's team of Advisors

Kadimastem appointed Mr. Ofer Haviv as a director

The new Chief Scientist, Mr. Avi Hasson visits Kadimastem

The Chief Scientist visits Kadimastem

© 2020 by Kadimastem

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon